[Ikaros Family Zinc Finger 1 Mutation Is an Adverse Prognostic Factor for Patients with Adult B-Cell Acute Lymphoblastic Leukemia].

OBJECTIVE: To investigate the prognosis of patients with adult B-cell acute lymphoblastic leukemia (B-ALL) accompanied with Ikaros family zinc finger 1 (IKZF1) mutation, and to explore the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in improving the clinical outcome of patients. METHODS: The clinical data of 164 adult B-ALL patients who received IKZF-1 mutation detection by capillary electrophoresis of bone marrow were collected, and the relationship between the IKZF-1 gene mutation and the prognosis of adult B-ALL patients was analyzed. RESULTS: Among 164 adult B-ALL patients, the patients with IKZF-1 mutation (IKZF-1(+)) were 80 cases, while the patients without IKZF-1 mutation (IKZF-1(-)) were 84 cases. Among 80 IKZF-1 positive patients, according to the treatment method after complete remission these patients were divided into HSCT group (48 cases) and chemotherapy group (32 cases). Analysis showed that the 3-year overall survival (OS) and leukemia-free survival (LFS) rates in the IKZF1(+) group were much lower. The OS and LFS rate in transplantation group were 50.3%+/-8.3%, 41.6%+/-8.5%; the OS and LFS rates in the chemotherapy group were 33.7%+/-12.8%, 31.5%+/-9.5%, which were lower than those in the IKZF1(-) group (the transplantation group: 79.5%+/-7.6%, 64.0%+/-8.4%; the chemotherapy group: 54.4%+/-9.9%, 40.6%+/-9.6% respectirely (P0.05). Among 80 B-ALL patients with IKZF-1(-) mutation, the 3-year OS and LFS rates were significantly higher in the transplantation group (55.3%+/-7.5%, 48.3%+/-7.6%) than those in the chemotherapy group (32.9%+/-11.8%, 28.4%+/-10.3%) with IKZF1 mutation (P0.05). CONCLUSION: IKZF1 mutation is an adverse prognostic factor for adult B-ALL patients, However, allo-HSCT significantly improves the OS and LFS of patients and also their clinical outcomes.